Quarterly report pursuant to Section 13 or 15(d)

Stock Warrants

v3.23.2
Stock Warrants
6 Months Ended
Jun. 30, 2023
Text Block [Abstract]  
Stock Warrants

10. Stock Warrants

As of June 30, 2023 and December 31, 2022, the Company had warrants to purchase the underlying common stock outstanding as shown in the table below.

 

 

June 30,
2023

 

 

December 31,
2022

 

Class C Warrants

 

 

1,406,977

 

 

 

 

Class D Warrants

 

 

5,627,906

 

 

 

 

2022 Warrants

 

 

 

 

 

2,034,883

 

2020 Warrants

 

 

 

 

 

110,248

 

Pfizer Warrant

 

 

 

 

 

6,320

 

Warrants to purchase common stock

 

 

7,034,883

 

 

 

2,151,451

 

Weighted-average exercise price per share

 

$

1.36

 

 

$

31.00